|| Protez Pharmaceuticals ||

News - Meeting The Urgent Need For New Antibiotics

	Jun 2008 Protez to be acquired by Novartis

	May 2008 Protez Initiates Phase II Study for Its Lead Product PZ-601 in Infectious Diseases

	Apr 2008 PZ-601 (SMP-601) data showing stability to beta-lactamases presented at ECCMID 2008

	Dec 2007 Protez Pharmaceuticals Receives Top “Emerging Life Sciences Company” Award

	Sep 2007 PZ-601 (SMP-601) Phase I multiple dose results, dose modeling and expanded microbiology presented at ICAAC 2007

	Apr 2007 PZ-601 (SMP-601) data including Phase I single dose results presented at ECCMID 2007

	Sep 2006 PZ-601 (SMP-601) highlights presented at ICAAC 2006

	Sep 2006 PZ-601 (SMP-601) data presented at ICAAC 2006

	Apr 2006 Protez Caps Series B Round at $21 Million – Files Phase 1 Clinical Trial Application

	Apr 2006 Clarence L. Young, M.D. Joins Protez Pharmaceuticals as Chief Medical Officer

	Aug 2005 Protez Pharmaceuticals Closes $15 Million Financing

	May 2005 Protez Announces Licensing Agreement with Sumitomo Pharmaceuticals Co., Ltd.

	Feb 2004 BioAdvance Award - Protez profile

	Feb 2004 BioAdvance announces recipients of funding

	Feb 2004 BTG Completes Series A Investment in Protez Pharmaceuticals Inc.